Selected Grants
A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67CuSAR-BBN for identification and treatment of RPRexpressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA617
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2028DoD: PCRP Clinical Consortium: Duke University Clinical Research Site
ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02
Clinical TrialPrincipal Investigator · Awarded by Propella Therapeutics Inc · 2022 - 2026Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site Award
ResearchCo-Principal Investigator · Awarded by Department of Defense · 2024 - 2026ODYSSEY Registry for Renal Cell Carcinoma
ResearchPrincipal Investigator · Awarded by Duke Clinical Research Institute · 2022 - 2026Title A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (Substudy U03A)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2026A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCIN
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2025A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03):
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2021 - 2025A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2015 - 2025Phase II Single Arm Study of Gemcitabine and Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2025A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Clinical TrialPrincipal Investigator · Awarded by Merck · 2018 - 2025Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site
ResearchCo Investigator · Awarded by Department of Defense · 2021 - 2024A randomized, open-label, multicenter, Phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide or enzalutamide
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2020 - 2024STUDY/PROTOCOL TITLE AND PROTOCOL NUMBER: "A Phase II, Open-label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men with High Risk Prostate Cancer"; XL184-IST64
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2019 - 2024Merck LiteSpark-001: Advanced rCC progression after immunotherapy
ResearchPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2022 - 2023A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unr
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2023A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2018 - 2023Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2022True NTH Project
ResearchCo Investigator · Awarded by Movember Foundation · 2015 - 2021Cardiopulmonary Exercise Testing (CPET) in Patients Treated with Schedule 2/1 and 4/2 for Metastic Renal Cell Carcinoma: A Randomized Multi-Site Trial
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2021ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Clovis Oncology, Inc. · 2018 - 2020A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcin
Clinical TrialPrincipal Investigator · Awarded by Merck · 2017 - 2020Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
ResearchCollaborator · Awarded by Prostate Cancer Foundation · 2014 - 2020Ipilimumab and Nivolumab Combination Therapy: A Randomized Study of an Immediate versus Delayed Exercise Intervention with FuNctional Capacity and Quality of Life Evaluations in Subjects with Advanced
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2020Metastatic Renal Cell Cancer Registry (MaRCC Registry)
ResearchPrincipal Investigator · Awarded by Pfizer, Inc. · 2014 - 2020A Phase III, open-label, multi-center, randomized study to investigate the efficacy and safety of MPDL3280A
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2015 - 2020True NTH Project: Self-Management Portal & Decision Support
ResearchCo Investigator · Awarded by Movember Foundation · 2015 - 2019EXTEND PC: Safety and Efficacy of Exercise Training in Men Receiving Enzalutamide in Cominbation iwth Conventional Androgen Deprivation Therapy for Hormone Naive Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Medivation, Inc. · 2014 - 2019Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum Resistant Metastatic Urothelial Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Acerta Pharma · 2015 - 2019Bladder Cancer in Older Adults - Treatment and Outcomes
ResearchCo Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2016 - 2017A Phase 2, Randomized, 3-Arm Study of Abiraterone Acetate alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix alone for Patients with Prostate Cancer with a Rise PSA or a Rising PSA and Nodal Disease Following Definitive ...
Clinical TrialPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2014 - 2017RNA Extraction and Amplification from Biopsy Specimens in Subjects with Metastatic Renal Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Argos Therapeutics, Inc. · 2013 - 2017External Relationships
- Eisai
- Telix pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.